FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

18 Jul 16

Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker Discovery and Testing for a Global Drug Development Program in Hematologic Cancers (read more...)

- CGI will provide comprehensive, biomarker-based patient profiling using technologies such as next generation sequencing (NGS) to provide (read more...)
30 Jun 16

Cancer Genetics, Inc. Receives New York State Approval for Focus::CLL™, a Unique NGS Panel for Chronic Lymphocytic Leukemia, Reinforcing the Company’s Market-Leading Position in the Diagnosis and Management of B-Cell Cancers (read more...)

- Focus::CLL™ is the only CLIA-validated and NYS-approved NGS panel for CLL that offers information for patient risk stratification, disease (read more...)

Events

Clinicians
Patients